SCHEMBL21259109

SCHEMBL21259109

Cc1cc2[nH]ncc2cc1Nc1cc(-c2ccc(-n3cccn3)cc2)[nH]n1

nearest known ligand 0.72

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ TNIK Q9UKE5 20/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21248144 0.84 TNIK (1.00) TNIK
SCHEMBL22975142 0.83 TNIK (0.66) TNIK
SCHEMBL21259144 0.82 TNIK (0.68) TNIK
SCHEMBL21259138 0.82 TNIK (0.66) TNIK
SCHEMBL26337435 0.81 TNIK (0.68) TNIK
SCHEMBL31203630 0.81 TNIK (0.81) TNIK
SCHEMBL21247564 0.80 TNIK (1.00) TNIK
SCHEMBL29914226 0.80 TNIK (0.67) TNIK
SCHEMBL21259097 0.80 TNIK (0.67) TNIK
SCHEMBL22978350 0.78 TNIK (0.64) TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3749647-B1 N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER KOREA RES INST CHEMICAL TECH (KR) 2023-09-27 — — EP disclosed
EP-3749647-B1 N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER KOREA RES INST CHEMICAL TECH (KR) 2023-09-27 — — EP disclosed
US-11447469-B2 Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-09-20 — — US disclosed
US-20210047300-A1 HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2021-02-18 — — US disclosed
US-20210047300-A1 HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2021-02-18 — — US disclosed
WO-2019156438-A1 HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210047300-A1 HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF TNNI3K, TNK1, TNIK TNIK 3/4885
US-11447469-B2 Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof TNNI3K, TNK1, TNIK TNIK 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback